ClinicalTrials.gg

Program

telitacicept

Also written as “Telitacicept”, “RC18 160mg” and “RC18 240mg”.

Its studies are mostly in Lupus Erythematosus, Systemic · Glomerulonephritis, IGA · Myasthenia Gravis · Sjogren's Syndrome · Lymphoma, Follicular, led by 3 companies.

Furthest: phase 3, since Jan 8, 201725 company-led studies, 8 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
RemeGen194 open or runningphase 3since Jan 8, 2017Aug 24, 2016Dec 31, 2026phase 3 · NCT07249632
Vor Biopharma42 open or runningphase 3since Mar 23, 2022Mar 23, 2022Mar 2027phase 3 · NCT06456580
Innovent Biologics22 open or runningphase 2since Sep 13, 2026Sep 13, 2026Jan 31, 2027phase 1 · NCT07886476

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Aug 24, 2016.

  1. May 21, 2021Phase 2 study in Glomerulonephritis, IGARemeGen · NCT04905212 · 15 enrolled · United States
  2. Jan 26, 2022Phase 1 study in Lupus Erythematosus, SystemicRemeGen · NCT05247203 · 92 enrolled · China
  3. Mar 23, 2022Vor Biopharma's first study: phase 3 study in Lupus Erythematosus, SystemicNew to Vor BiopharmaVor Biopharma · NCT05306574 · 91 enrolled · United States, Argentina, Australia and more
  4. Dec 26, 2022Phase 2 study in Lupus NephritisRemeGen · NCT05680480 · 120 planned · China
  5. Dec 29, 2022Phase 3 study in Primary Sjogren's SyndromeRemeGen · NCT05673993 · 381 enrolled · China
  6. Jan 8, 2023Phase 1 study in Lupus Erythematosus, SystemicRemeGen · NCT05687526 · 16 enrolled · China
  7. Feb 12, 2023Phase 3 study in Myasthenia GravisRemeGen · NCT05737160 · 114 enrolled · China
  8. Mar 5, 2023Phase 3 study in Glomerulonephritis, IGARemeGen · NCT05799287 · 318 enrolled · China
  9. Jun 7, 20242 phase 3 studiesVor Biopharma · NCT06456580, NCT06456567
  10. Nov 18, 2025Phase 3 study in Myasthenia GravisRemeGen · NCT07249632 · 120 planned · China
  11. Feb 4, 2026Phase 3 study in Sjogren's SyndromeVor Biopharma · NCT07404865 · 250 planned · United States, Georgia
  12. Mar 9, 2026Phase 3 study in CTD-ILDRemeGen · NCT07495033 · 260 planned · China
  13. Sep 13, 2026Innovent Biologics's first study: phase 2 study in Sjogren's SyndromeNew to Innovent BiologicsInnovent Biologics · NCT07836660 · 198 planned · China
  14. Oct 8, 2026Phase 1 study in Glomerulonephritis, IGAInnovent Biologics · NCT07886476 · 100 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Myasthenia GravisRemeGen · NCT07249632
  2. Jan 31, 2027Primary completion: phase 1 study in Glomerulonephritis, IGAInnovent Biologics · NCT07886476
  3. Mar 2027Primary completion: phase 3 study in Myasthenia GravisVor Biopharma · NCT06456580
  4. Nov 1, 2027Primary completion: phase 2 study in Sjogren's SyndromeInnovent Biologics · NCT07836660

TargetBeta

TNFRSF13B →read by rule
“A fusion protein composed of the extracellular domain of human tumor necrosis factor receptor superfamily member 13B (TNFRSF13B; transmembrane activator and calcium modulator and cyclophilin ligand interactor; TACI) ”NCIt, by rule

Other programs on TNFRSF13B

ProgramCompanyFurthest phaseStudies
povetaciceptruleVertex Pharmaceuticalsphase 39
SHR-2173Jiangsu HengRui Medicinephase 28

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07886476Glomerulonephritis, IGA · China1Not yet recruitingInnovent BiologicsJan 31, 2027100
NCT07836660Sjogren's Syndrome · China2Not yet recruitingInnovent BiologicsNov 1, 2027198
NCT07495033CTD-ILD · China3Not yet recruitingRemeGenMay 31, 2029260
NCT07404865Sjogren's Syndrome · United States, Georgia3RecruitingVor BiopharmaDec 2028250
NCT07249632Myasthenia Gravis · China3RecruitingRemeGenDec 31, 2026120
NCT06456580Myasthenia Gravis · United States, Argentina, Australia and more3Active, not recruitingVor BiopharmaMar 2027191
NCT06456567Lupus Erythematosus, Systemic · United States3WithdrawnVor BiopharmaJan 2, 20250
NCT05799287Glomerulonephritis, IGA · China3Active, not recruitingRemeGenJun 2026318
NCT05737160Myasthenia Gravis · China3CompletedRemeGenNov 26, 2024114
NCT05687526Lupus Erythematosus, Systemic · China1CompletedRemeGenNov 14, 202516
NCT05673993Primary Sjogren's Syndrome · China3CompletedRemeGenOct 29, 2024381
NCT05680480Lupus Nephritis · China2RecruitingRemeGenDec 2025120
NCT05306574Lupus Erythematosus, Systemic · United States, Argentina, Australia and more3TerminatedVor BiopharmaJan 6, 202591
NCT05247203Lupus Erythematosus, Systemic · China1CompletedRemeGenOct 25, 202392
NCT04905212Glomerulonephritis, IGA · United States2TerminatedRemeGenNov 9, 202315
NCT04625153Multiple Sclerosis, Relapsing-Remitting · China2TerminatedRemeGenApr 3, 20268
NCT04302103Systemic Myasthenia Gravis · China2CompletedRemeGenJan 14, 202229
NCT04291781Glomerulonephritis, IGA · China2CompletedRemeGenMay 20, 202144
NCT04235933Healthy · China1CompletedRemeGenDec 20, 201936
NCT04082416Lupus Erythematosus, Systemic · China3CompletedRemeGenApr 24, 2022335
NCT04078386Primary Sjögren's Syndrome · China2CompletedRemeGenJun 23, 202142
NCT03330418Neuromyelitis Optica · China3TerminatedRemeGenApr 3, 2026178
NCT03016013Lymphoma, Follicular · China3CompletedRemeGenNov 19, 2022479
NCT02885610Lupus Erythematosus, Systemic · China2CompletedRemeGenJun 11, 2019249
NCT02882087Lymphoma, Follicular · China2TerminatedRemeGenFeb 25, 201960

How it is read

Names in the registry

  • “Telitacicept”, 11 entries
  • “RC18 160mg”, 3 entries
  • “RC18 240mg”, 3 entries
  • “RC18 240 mg”, 2 entries
  • “RC18 160 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.